Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.
Pavord ID., Buhl R., Kraft M., Prazma CM., Price RG., Howarth PH., Yancey SW.
In patients with severe eosinophilic asthma and sputum eosinophil counts of ≥3-<30%, sputum eosinophils may not represent a more useful biomarker than blood eosinophils for predicting clinical treatment response to mepolizumab https://bit.ly/3pOTw93.